Recombinant Human ARHGAP5 293 Cell Lysate

• Cat.No.: ARHGAP5-8737HCL

Specification

• Description: Antigen standard for Rho GTPase activating protein 5 (ARHGAP5), transcript variant 2 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ARHGAP5 Rho GTPase activating protein 5 [ Homo sapiens ]
• Official Symbol: ARHGAP5
• Synonyms: ARHGAP5; Rho GTPase activating protein 5; GFI2, growth factor independent 2; rho GTPase-activating protein 5; p190 B; p190BRhoGAP; RhoGAP5; p105 RhoGAP; growth factor independent 2; p100 RasGAP-associated p105 protein; rho-type GTPase-activating protein 5; GFI2; p190-B
• Gene ID: 394
• mRNA Refseq: NM_001030055
• Protein Refseq: NP_001025226
• MIM: 602680
• UniProt ID: Q13017
• Chromosome Location: 14q12
• Pathway: Focal Adhesion, organism-specific biosystem; Focal adhesion, organism-specific biosystem; Focal adhesion, conserved biosystem; Leukocyte transendothelial migration, organism-specific biosystem; Leukocyte transendothelial migration, conserved biosystem; RAC1 signaling pathway, organism-specific biosystem; Regulation of RhoA activity, organism-specific biosystem
• Function: GTP binding; GTPase activator activity; GTPase activity; Rho GTPase activator activity; SH2 domain binding

Reviews

12/17/2022

With their meticulous documentation and support, I am confident that my utilization of ARHGAP5 protein in clinical trials will meet all necessary regulations and guidelines.

08/24/2022

the excellent technical support provided by the manufacturer is of immense value to me.

08/18/2021

In addition to the remarkable quality of the protein, the manufacturer's support extends beyond the provision of the product itself.

05/07/2020

The ability to customize the ARHGAP5 protein variants or modifications offered by the manufacturer is also advantageous, as it allows me to tailor the protein to my specific research objectives.

03/15/2019

Manufacturers should ensure the consistency and quality of ARHGAP5 protein products.

03/07/2018

Additionally, cost-effectiveness, competitive pricing, and bulk purchase options can also be advantageous for researchers working within limited budgets.

10/31/2017

I appreciate the manufacturer's commitment to maintaining exceptional protein quality standards, which ensures reliable and consistent results in my trials.

08/27/2017

Its purity, stability, and functionality make it an ideal choice for my research endeavors.

09/17/2016

The ARHGAP5 protein offered by the manufacturer exhibits exceptional quality and is precisely tailored to meet my experimental requirements.

07/10/2016

A manufacturer that offers customization options can enable the researcher to adhere to their experimental design requirements more effectively.

Q&As

Are there any known diseases or disorders associated with ARHGAP5?

While ARHGAP5 mutations have been linked to intellectual disability and developmental delay in some cases, there are no specific diseases or disorders that are primarily associated with ARHGAP5 dysfunction. However, given its role in essential cellular processes like cell migration and adhesion, dysregulation of ARHGAP5 may potentially contribute to various diseases, including cancer, cardiovascular diseases, and neurological disorders. Further research is needed to uncover the specific implications of ARHGAP5 in these conditions.

Are there any known mutations or genetic variants in the ARHGAP5 gene?

Yes, mutations and genetic variants in the ARHGAP5 gene have been reported. For example, some studies have identified ARHGAP5 mutations in patients with intellectual disability and developmental delay. Additionally, certain genetic variants in ARHGAP5 have been associated with susceptibility to certain conditions and diseases, such as myocardial infarction and hypertension. However, further research is needed to fully understand the impact of these mutations and variants on ARHGAP5 function and disease development.

How is ARHGAP5 involved in cell migration?

ARHGAP5 is involved in cell migration by regulating the activity of Rho GTPases, particularly RhoA, Rac1, and CDC42. These GTPases play key roles in actin cytoskeletal dynamics, which are critical for cell migration. ARHGAP5 functions as a GAP, catalyzing the hydrolysis of GTP bound to these GTPases, thereby converting them from an active GTP-bound state to an inactive GDP-bound state. This inactivation of Rho GTPases ultimately leads to the remodeling of the actin cytoskeleton and the regulation of cell migration.

Is ARHGAP5 involved in cancer progression?

Yes, ARHGAP5 has been implicated in cancer progression and metastasis. Its regulation of Rho GTPases, particularly RhoA, Rac1, and CDC42, influences key processes involved in cancer metastasis, such as cell migration, invasion, and adhesion. Modulation of ARHGAP5 expression or activity can affect tumor cell behavior and metastatic potential, making it an important factor in cancer biology. However, more research is needed to fully elucidate the specific mechanisms by which ARHGAP5 contributes to cancer progression and to explore its potential as a therapeutic target.

In which tissues or organs is ARHGAP5 predominantly expressed?

ARHGAP5 is expressed in various tissues and cell types. It is most abundant in tissues with high cellular turnover and active migration processes, such as the brain, lung, kidney, and intestines. However, ARHGAP5 expression levels can vary across different cell types within these tissues. For example, in the brain, ARHGAP5 is mainly expressed in the hippocampus, which is involved in learning and memory. Further studies are needed to better understand the tissue-specific expression and cellular localization of ARHGAP5.

Can ARHGAP5 be phosphorylated or post-translationally modified?

Yes, ARHGAP5 can undergo post-translational modifications, including phosphorylation. Phosphorylation of ARHGAP5 at specific sites can regulate its activity and interactions with other proteins. For example, phosphorylation of ARHGAP5 by protein kinases like PAK1 and Aurora A can modulate its ability to interact with Rho GTPases and regulate their activity. Other post-translational modifications, such as acetylation and ubiquitination, have also been suggested to potentially impact ARHGAP5 function. Understanding the precise role of these modifications is an active area of research.

Does ARHGAP5 have any role in neuronal development or function?

The expression and function of ARHGAP5 in neuronal development and function have not been extensively studied. However, Rho GTPases, which are regulated by ARHGAP5, are known to play important roles in neuronal processes such as neurite outgrowth, axon guidance, and synapse formation. It is possible that ARHGAP5, as a regulator of Rho GTPase activity, may also contribute to these processes. Further research is needed to determine the specific involvement of ARHGAP5 in neuronal development and function.

Are there any known interacting proteins of ARHGAP5?

Yes, ARHGAP5 interacts with several proteins to modulate its activity and function. For example, ARHGAP5 has been shown to interact with paxillin, a focal adhesion protein involved in cell adhesion and migration. This interaction suggests a role for ARHGAP5 in regulating focal adhesion dynamics. Additionally, ARHGAP5 has been found to interact with other proteins involved in Rho GTPase signaling pathways, including the Rho GTPases themselves, regulatory proteins like Rho guanine nucleotide exchange factors (GEFs), and other GAPs. These protein interactions likely contribute to the precise regulation of ARHGAP5 activity and downstream cellular processes.

Can ARHGAP5 be targeted for therapeutic interventions?

Targeting ARHGAP5 for therapeutics is a possibility, considering its involvement in various cellular processes and its potential role in diseases such as cancer. However, further research is needed to fully understand the functions and regulatory mechanisms of ARHGAP5, as well as its specific roles in disease pathogenesis. Developing targeted therapies that selectively modulate ARHGAP5 activity without affecting other essential cellular functions may present a challenge. Nevertheless, exploring the therapeutic potential of ARHGAP5 is an area of interest for future research.